PD‐1 inhibitors (e.g., Nivolumab, Pembrolizumab) were primarily associated with hepatitis and liver function abnormalities, whereas PD‐L1 inhibitors (e.g., Durvalumab, Atezolizumab) were more frequently linked to immune‐mediated liver disease and liver failure. The gene discussed is CD274; the disease is hepatitis A virus infection.